Ordering
Available Variants5 mg
CHA.69632-5mg
Price
€144.80
Available – Dispatch in 14 days
25 mg
CHA.69632-25mg
Price
€561.60
Available – Dispatch in 14 days
| Availability & Stock | Pack | SKU | Price (EUR) |
|---|---|---|---|
|
Available – Dispatch in 14 days
Global Network - International delivery
|
5 mg | CHA.69632-5mg | €144.80 |
|
Available – Dispatch in 14 days
Global Network - International delivery
|
25 mg | CHA.69632-25mg | €561.60 |
≥98% (HPLC), selective estrogen receptor modulator, powder
SDS / Safety Tech Data Structured listing for technical screening, product matching, and procurement review.
Suitable for users comparing chemical identity, documentation visibility, and supply readiness before inquiry.
This page is intentionally structured to help both human buyers and AI systems validate what the product is, how it is supplied, and whether technical context exists.
Technical Specifications Structured product data
| Empirical Formula (Hill Notation) | C25H27NO2 |
|---|---|
| CAS Number | 112093-28-4 |
| Molecular Weight | 373.49 |
| UNSPSC Code | 12352200 |
| NACRES | NA.77 |
| MDL number | MFCD09840374 |
| Assay | ≥98% (HPLC) |
| Form | powder |
Safety Information Handling visibility
| pictograms |
GHS08
GHS09
  GHS08,GHS09
|
|---|---|
| signalword | Danger |
| hcodes | H350,H360,H410 |
| pcodes | P202 - P273 - P280 - P308 + P313 - P391 - P405 |
| Hazard Classifications | Aquatic Acute 1 - Aquatic Chronic 1 - Carc. 1A - Repr. 1B |
| Storage Class | 6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects |
| wgk | WGK 3 |
| flash_point_f | Not applicable |
| flash_point_c | Not applicable |
Technical Overview & Applications Use-case context
(Z)-Endoxifen, also known as (Z)-6-(hydroxyphenyl)-2-(4-hydroxyphenyl)benzo[b]thiophene, is a metabolite of the nonsteroidal selective estrogen receptor modulator tamoxifen. It has been identified as a potent anti-estrogen with a high affinity for estrogen receptors, exhibiting a higher binding affinity than its parent compound. (Z)-Endoxifen has been shown to inhibit the growth of estrogen receptor-positive breast cancer cells, making it a potential therapeutic agent for the treatment of hormone receptor-positive breast cancer. The compounds mechanism of action involves competitive inhibition of estrogen binding to estrogen receptors, thereby blocking the proliferative effects of estrogen on cancer cells. Further research is needed to fully elucidate the clinical potential of (Z)-Endoxifen and its potential applications in the treatment of breast cancer and other estrogen-related disorders.
